Patient characteristics
| Characteristic . | Total . | Lost to follow-up . | No QRISK . | QRISK . |
|---|---|---|---|---|
| Number | 709 | 22 | 108 | 579 |
| Age, mean ± SD, y | 48 ± 13.4 | 47 ± 15.0 | 64 ± 14.0 | 46 ± 11.7 |
| From the United Kingdom | 45.3% (321) | 72.7% (16) | 59.3% (64) | 41.6% (241) |
| Hemophilia A | 83.8% (594) | 72.7% (16) | 82.4% (89) | 84.5% (489) |
| Severity | ||||
| Severe | 48.5% (344) | 13.6% (3) | 59.3% (64) | 52.5% (304) |
| Moderate | 11.7% (83) | 9.1% (2) | 6.5% (7) | 12.8% (74) |
| Mild | 39.8% (282) | 77.3% (17) | 59.3% (64) | 34.7% (201) |
| QRISK (5 y), mean ± SD | 2.0 ± 5.41 | 1.30 ± 4.91 | NA | 2.0 ± 5.42 |
| Previous CVD | 8.6% (61) | 9.1% (2) | 46.3% (50) | 1.6% (9)* |
| Cholesterol/HDL ratio, mean ± SD | 4.31 ± 1.54 | 4.15 ± 1.36 | 4.0 ± 1.13† | 4.36 ± 1.60 |
| Systolic blood pressure, mean ± SD, mm Hg | 135 ± 16.6 | 135 ± 20.6 | 137 ± 19.5 | 134 ± 15.8 |
| Hypertension | 48.8% (346) | 45.5% (10) | 78.7% (85) | 43.4% (251) |
| HIV infection | 10.7% (76) | 4.5% (1) | 7.4% (8) | 11.6% (67) |
| Active HCV infection | 32.2% (228) | 27.2% (6) | 17.6% (19) | 35.1% (203) |
| Diabetes mellitus | 6.1% (43) | 4.5% (1) | 17.6% (19) | 4.0% (23) |
| Rheumatoid arthritis | 1.1% (8) | 0 | 1.9% (2) | 1% (6) |
| Active smoking | 27.6% (196) | 18.2% (4) | 18.5% (20) | 29.7% (172) |
| BMI, mean ± SD, kg/m2 | 25.7 ± 4.1 | 26.37 ± 4.3 | 26.9 ± 4.5 | 25.5 ± 4.0 |
| Family history coronary heart disease | 35% (248) | 36.4% (8) | 45.4% (49) | 33.0% (191) |
| Atrial fibrillation | 2.3% (16) | 0% (0) | 9.3% (10) | 1.0% (6) |
| Chronic kidney disease (stage 4 or 5) | 0.1% (1) | 0% (0) | 0.9% (1) | 0% (0) |
| Characteristic . | Total . | Lost to follow-up . | No QRISK . | QRISK . |
|---|---|---|---|---|
| Number | 709 | 22 | 108 | 579 |
| Age, mean ± SD, y | 48 ± 13.4 | 47 ± 15.0 | 64 ± 14.0 | 46 ± 11.7 |
| From the United Kingdom | 45.3% (321) | 72.7% (16) | 59.3% (64) | 41.6% (241) |
| Hemophilia A | 83.8% (594) | 72.7% (16) | 82.4% (89) | 84.5% (489) |
| Severity | ||||
| Severe | 48.5% (344) | 13.6% (3) | 59.3% (64) | 52.5% (304) |
| Moderate | 11.7% (83) | 9.1% (2) | 6.5% (7) | 12.8% (74) |
| Mild | 39.8% (282) | 77.3% (17) | 59.3% (64) | 34.7% (201) |
| QRISK (5 y), mean ± SD | 2.0 ± 5.41 | 1.30 ± 4.91 | NA | 2.0 ± 5.42 |
| Previous CVD | 8.6% (61) | 9.1% (2) | 46.3% (50) | 1.6% (9)* |
| Cholesterol/HDL ratio, mean ± SD | 4.31 ± 1.54 | 4.15 ± 1.36 | 4.0 ± 1.13† | 4.36 ± 1.60 |
| Systolic blood pressure, mean ± SD, mm Hg | 135 ± 16.6 | 135 ± 20.6 | 137 ± 19.5 | 134 ± 15.8 |
| Hypertension | 48.8% (346) | 45.5% (10) | 78.7% (85) | 43.4% (251) |
| HIV infection | 10.7% (76) | 4.5% (1) | 7.4% (8) | 11.6% (67) |
| Active HCV infection | 32.2% (228) | 27.2% (6) | 17.6% (19) | 35.1% (203) |
| Diabetes mellitus | 6.1% (43) | 4.5% (1) | 17.6% (19) | 4.0% (23) |
| Rheumatoid arthritis | 1.1% (8) | 0 | 1.9% (2) | 1% (6) |
| Active smoking | 27.6% (196) | 18.2% (4) | 18.5% (20) | 29.7% (172) |
| BMI, mean ± SD, kg/m2 | 25.7 ± 4.1 | 26.37 ± 4.3 | 26.9 ± 4.5 | 25.5 ± 4.0 |
| Family history coronary heart disease | 35% (248) | 36.4% (8) | 45.4% (49) | 33.0% (191) |
| Atrial fibrillation | 2.3% (16) | 0% (0) | 9.3% (10) | 1.0% (6) |
| Chronic kidney disease (stage 4 or 5) | 0.1% (1) | 0% (0) | 0.9% (1) | 0% (0) |
Characteristics of all patients included, lost to follow-up, patients with complete follow-up in whom a QRISK score was calculable, and those without a QRISK score.
BMI, body mass index; HCV, hepatitis C virus; NA, not available; SD, standard deviation.
Nine patients had a history of nonthrombotic CVD, such as nonischemic heart failure, atrial fibrillation, and hemorrhagic stroke. A QRISK score was therefore applicable.
A significant portion of patients without a QRISK score are on statin therapy, lowering the cholesterol/high-density lipoprotein (HDL) ratio.